Brain Stimulation Clinical Trial
Official title:
Assessing the Physiologic Effect of taVNS During a Cold Pressor Test
Verified date | January 2024 |
Source | Medical University of South Carolina |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study explores the use of transcutaneous auricular vagus nerve stimulation (taVNS), a new form of neuromodulation which stimulates the ear. 24 healthy subjects without a past medical or psychiatric history will be recruited to participate in a phone screen followed by 1 lab visit. During the lab visit, subjects will participate twice in a validated stress induction technique called the cold pressor test, while concurrently receiving either active or sham taVNS. The cold pressor test consists of subjects placing their feet in an ice bath for a short period of time. Researchers will measure participant's heart rate while they receive taVNS (ear stimulation) and participate in the cold pressor test. Assessments of mood, anxiety, and stress will be collected at the beginning and end of the visit.
Status | Completed |
Enrollment | 24 |
Est. completion date | December 20, 2021 |
Est. primary completion date | December 20, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Ages 18-65 years - English speaking - Non-treatment-seeking community members Exclusion Criteria: - Diagnosis of COVID-19 in the past 14 days - Facial or ear pain or recent ear trauma. - Metal implant devices in the head, heart or neck. - History of brain stimulation or other brain surgery. - History of myocardial infarction or arrhythmia, bradycardia. - Use of B-blockers, antiarrhythmic medication (sodium/potassium/calcium-channel blockers), or blood pressure medications. - Active respiratory disorder. - Personal or family history of seizure or epilepsy or personal use of medications that substantially reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium). - Personal history of head injury, concussion, or self-report of moderate to severe traumatic brain injury. - Individuals suffering from frequent/severe headaches. - Individuals with a reported history of any mental health disorder or taking any psychotropic medications. - Moderate to severe alcohol or substance use disorder. - Pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina | National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Heart Rate (Before CPT/taVNS) | Heart rate will be measured with EKG electrodes before concurrent stress test and ear stimulation. | Baseline (up to 10 minutes prior to concurrent stress test and ear stimulation) | |
Primary | Mean Heart Rate (During CPT/taVNS) | Heart rate will be measured with EKG electrodes during concurrent stress test and ear stimulation. | During concurrent stress test and ear stimulation (average duration of 5 minutes) | |
Primary | Mean Heart Rate (After CPT/taVNS) | Heart rate will be measured with EKG electrodes after concurrent stress test and ear stimulation. | After concurrent stress test and ear stimulation (up to 10 minutes after concurrent stress test and ear stimulation) | |
Secondary | Mean Score of Pain (Before CPT/taVNS) | Pain will be assessed using a 0-10 scale (where 0 represents no pain at all and 10 represents the worst pain possible) before concurrent stress test and ear stimulation. | Baseline (up to 10 minutes prior to concurrent stress test and ear stimulation) | |
Secondary | Mean Score of Pain (During CPT/taVNS) | Pain will be assessed using a 0-10 scale (where 0 represents no pain at all and 10 represents the worst pain possible) during concurrent stress test and ear stimulation. | During concurrent stress test and ear stimulation (average duration of 5 minutes) | |
Secondary | Mean Score of Pain (After CPT/taVNS) | Pain will be assessed using a 0-10 scale (where 0 represents no pain at all and 10 represents the worst pain possible) after concurrent stress test and ear stimulation. | After concurrent stress test and ear stimulation (up to 10 minutes after concurrent stress test and ear stimulation) | |
Secondary | Mean Score of Anxiety (Before CPT/taVNS) | Anxiety will be assessed using a 0-10 scale (where 0 represents no anxiety at all and 10 represents the worst anxiety possible) before concurrent stress test and ear stimulation. | Baseline (up to 10 minutes prior to concurrent stress test and ear stimulation) | |
Secondary | Mean Score of Anxiety (During CPT/taVNS) | Anxiety will be assessed using a 0-10 scale (where 0 represents no anxiety at all and 10 represents the worst anxiety possible) during concurrent stress test and ear stimulation. | During concurrent stress test and ear stimulation (average duration of 5 minutes) | |
Secondary | Mean Score of Anxiety (After CPT/taVNS) | Anxiety will be assessed using a 0-10 scale (where 0 represents no anxiety at all and 10 represents the worst anxiety possible) after concurrent stress test and ear stimulation. | After concurrent stress test and ear stimulation (up to 10 minutes after concurrent stress test and ear stimulation) | |
Secondary | Mean Score of Distress (Before CPT/taVNS) | Distress will be assessed using a 0-10 scale (where 0 represents no distress at all and 10 represents the worst distress possible) before concurrent stress test and ear stimulation. | Baseline (up to 10 minutes prior to concurrent stress test and ear stimulation) | |
Secondary | Mean Score of Distress (During CPT/taVNS) | Distress will be assessed using a 0-10 scale (where 0 represents no distress at all and 10 represents the worst distress possible) during concurrent stress test and ear stimulation. | During concurrent stress test and ear stimulation (average duration of 5 minutes) | |
Secondary | Mean Score of Distress (After CPT/taVNS) | Distress will be assessed using a 0-10 scale (where 0 represents no distress at all and 10 represents the worst distress possible) after concurrent stress test and ear stimulation. | After concurrent stress test and ear stimulation (up to 10 minutes after concurrent stress test and ear stimulation) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04148547 -
Transcranial Direct Current Stimulation (tDCS) in the Primary Motor Cortex in Healthy Individuals
|
N/A | |
Completed |
NCT05544201 -
Transcranial Alternating Current Stimulation (TACS) for Sleep Disturbances in Neurocognitive Disorders Due to Alzheimer's Disease
|
N/A | |
Completed |
NCT03720665 -
Cortical Excitability Changes on the Sensorimotor Cortex Induced by Caffeine Consumption: A TMS Study
|
N/A | |
Completed |
NCT02697110 -
Family Inclusive Early Brain Stimulation
|
N/A | |
Completed |
NCT04011670 -
Neuroplastic Alterations of the Motor Cortex by Caffeine
|
N/A | |
Completed |
NCT04046055 -
Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
|
N/A | |
Completed |
NCT02498574 -
Performance Enhancement and Non-Invasive Brain Stimulation
|
N/A |